# OnCo record stipple-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/stipple-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "stipple-bio" ;
  schema:name "Stipple Bio"@en ;
  schema:description "Stipple Bio looks for tiny regions on cancer-cell proteins that healthy cells do not show, then builds antibodies that bind only those regions. Its first medicine is an antibody-drug conjugate expected to start human trials in early 2027."@en ;
  schema:url <https://onco.cc/companies/stipple-bio/>, <https://stipple.bio/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://stipple.bio/>, <https://stipple.bio/stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a-precision-oncology-pipeline-that-leverages-its-pointil/>, <https://stipple.bio/pipeline/>, <https://stipple.bio/stipple-bio-enters-multi-target-license-agreement-with-lonza-to-advance-precision-oncology-adc-therapies/> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/> .